Citius Oncology, Inc. (CTOR)
0.80
+0.01
(+0.98%)
USD |
NASDAQ |
Sep 04, 13:54
Citius Oncology Enterprise Value : 77.43M for Sept. 3, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 03, 2026 | 77.43M |
| September 02, 2026 | 75.90M |
| September 01, 2026 | 72.97M |
| August 31, 2026 | 74.36M |
| August 28, 2026 | 75.67M |
| August 27, 2026 | 77.23M |
| August 26, 2026 | 76.89M |
| August 25, 2026 | 79.32M |
| August 24, 2026 | 72.97M |
| August 21, 2026 | 72.31M |
| August 20, 2026 | 73.93M |
| August 19, 2026 | 73.23M |
| August 18, 2026 | 68.00M |
| August 17, 2026 | 71.91M |
| August 14, 2026 | 89.87M |
| August 13, 2026 | 81.09M |
| August 12, 2026 | 79.47M |
| August 11, 2026 | 70.85M |
| August 10, 2026 | 71.64M |
| August 07, 2026 | 73.28M |
| August 06, 2026 | 74.02M |
| August 05, 2026 | 76.67M |
| August 04, 2026 | 63.45M |
| August 03, 2026 | 59.79M |
| July 31, 2026 | 56.29M |
| Date | Value |
|---|---|
| July 30, 2026 | 54.33M |
| July 29, 2026 | 50.37M |
| July 28, 2026 | 50.90M |
| July 27, 2026 | 52.45M |
| July 24, 2026 | 53.10M |
| July 23, 2026 | 54.80M |
| July 22, 2026 | 54.27M |
| July 21, 2026 | 53.93M |
| July 20, 2026 | 53.93M |
| July 17, 2026 | 66.50M |
| July 16, 2026 | 65.77M |
| July 15, 2026 | 66.49M |
| July 14, 2026 | 62.39M |
| July 13, 2026 | 68.19M |
| July 10, 2026 | 66.73M |
| July 09, 2026 | 69.93M |
| July 08, 2026 | 70.84M |
| July 07, 2026 | 68.75M |
| July 06, 2026 | 68.62M |
| July 02, 2026 | 65.60M |
| July 01, 2026 | 68.13M |
| June 30, 2026 | 62.40M |
| June 29, 2026 | 65.45M |
| June 26, 2026 | 58.82M |
| June 25, 2026 | 62.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Citius Pharmaceuticals, Inc. | 15.99M |
| ACADIA Pharmaceuticals, Inc. | 3.913B |
| Alnylam Pharmaceuticals, Inc. | 35.05B |
| Anika Therapeutics, Inc. | 267.88M |
| Savara, Inc. | 960.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.924M |
| Revenue (Quarterly) | 1.494M |
| Total Expenses (Quarterly) | 10.42M |
| EPS Diluted (Quarterly) | -0.0827 |
| Gross Profit Margin (Quarterly) | -48.09% |
| Profit Margin (Quarterly) | -597.4% |
| Earnings Yield | -59.21% |
| Normalized Earnings Yield | -59.21 |